142 related articles for article (PubMed ID: 10231510)
1. Original articles: ease of wound closure as an endpoint of treatment efficacy.
Robson MC; Maggi SP; Smith PD; Wassermann RJ; Mosiello GC; Hill DP; Cooper DM
Wound Repair Regen; 1999; 7(2):90-6. PubMed ID: 10231510
[TBL] [Abstract][Full Text] [Related]
2. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
Rees RS; Robson MC; Smiell JM; Perry BH
Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
4. Use of becaplermin gel and Kollagen Medifil particles.
Tomaselli NL
J Wound Ostomy Continence Nurs; 2000 Nov; 27(6):319-20. PubMed ID: 11096412
[No Abstract] [Full Text] [Related]
5. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
Mustoe TA; Cutler NR; Allman RM; Goode PS; Deuel TF; Prause JA; Bear M; Serdar CM; Pierce GF
Arch Surg; 1994 Feb; 129(2):213-9. PubMed ID: 8304833
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ
Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
[TBL] [Abstract][Full Text] [Related]
7. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB.
Pierce GF; Tarpley JE; Allman RM; Goode PS; Serdar CM; Morris B; Mustoe TA; Vande Berg J
Am J Pathol; 1994 Dec; 145(6):1399-410. PubMed ID: 7992843
[TBL] [Abstract][Full Text] [Related]
8. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
Robson MC; Phillips LG; Thomason A; Robson LE; Pierce GF
Lancet; 1992 Jan; 339(8784):23-5. PubMed ID: 1345953
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
12. Use of topical recombinant human platelet-derived growth factor BB in abdominal wound separation.
Shackelford DP; Fackler E; Hoffman MK; Atkinson S
Am J Obstet Gynecol; 2002 Apr; 186(4):701-4. PubMed ID: 11967494
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
Victor-Vega C; Desai A; Montesinos MC; Cronstein BN
Inflammation; 2002 Feb; 26(1):19-24. PubMed ID: 11936752
[TBL] [Abstract][Full Text] [Related]
14. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.
LeGrand EK
Am J Surg; 1998 Aug; 176(2A Suppl):48S-54S. PubMed ID: 9777972
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
Castronuovo JJ; Ghobrial I; Giusti AM; Rudolph S; Smiell JM
Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of platelet-derived growth factor BB in accelerating wound healing in aged versus young animals: the impact of tissue hypoxia.
Wu L; Brucker M; Gruskin E; Roth SI; Mustoe TA
Plast Reconstr Surg; 1997 Mar; 99(3):815-22; discussion 823-4. PubMed ID: 9047202
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U; Willis M; Odegaard K; Apelqvist J
Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
[TBL] [Abstract][Full Text] [Related]
18. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial.
Senet P; Vicaut E; Beneton N; Debure C; Lok C; Chosidow O
Arch Dermatol; 2011 Aug; 147(8):926-30. PubMed ID: 21482863
[TBL] [Abstract][Full Text] [Related]
19. The future of recombinant growth factors in wound healing.
Robson MC; Mustoe TA; Hunt TK
Am J Surg; 1998 Aug; 176(2A Suppl):80S-82S. PubMed ID: 9777977
[TBL] [Abstract][Full Text] [Related]
20. 3 cases of aberrant wound healing in acute myelogenous leukemia.
Smith L; Gallison B; Siegler EL
Adv Skin Wound Care; 2005; 18(9):473-6. PubMed ID: 16365543
[No Abstract] [Full Text] [Related]
[Next] [New Search]